Stock CRBU CARIBOU BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Caribou Biosciences, Inc.

Equities

CRBU

US1420381089

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
2.88 USD +1.05% Intraday chart for Caribou Biosciences, Inc. -3.03% -49.74%
May. 09 Truist Adjusts Price Target on Caribou Biosciences to $19 From $21, Maintains Buy Rating MT
May. 07 Caribou Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences
Caribou Biosciences : Cas12a chRDNA in vivo editing ASGCT 2024
Truist Adjusts Price Target on Caribou Biosciences to $19 From $21, Maintains Buy Rating
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
Caribou Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Caribou Biosciences to Participate in Upcoming Investor Conferences
Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Caribou Biosciences : CB-010 ANTLER Case Study iwCAR-T 2024
Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Caribou Biosciences : CB-012 IND-enabling preclinical data AACR 2024
Sector Update: Health Care Stocks Lean Higher Pre-Bell Friday
Caribou Gets FDA Clearance For Phase 1 Testing of CB-010 Cell Therapy in Lupus Patients
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
Caribou Biosciences, Inc. Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
Poseida Therapeutics Appoints Syed Rizvi as Chief Medical Officer
HC Wainwright Adjusts Caribou Biosciences Price Target to $24 From $23, Maintains Buy Rating
Caribou Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Caribou Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRBU Stock
  4. News Caribou Biosciences, Inc.
  5. Other languages